Fusion Pharmaceuticals Inc. (FUSN) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED 2024
What happened to Fusion Pharmaceuticals Inc. (FUSN) stock?
Fusion Pharmaceuticals Inc. (FUSN) no longer trades on public markets. It was delisted in June 2024. The figures below are historical and are not a current quote.
Market cap $1.83B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Fusion Pharmaceuticals Inc. (FUSN). Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines.
Last analyzed: Sep 9, 2026Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc.
Analyst Coverage for FUSN: FUSN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FUSN against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 30 months old (Mar 1, 2024), so the figures and score below describe that period, not today.
FUSN: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Fusion Pharmaceuticals Inc. Company Overview
Who Are FUSN's Competitors?
FUSN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| VCEL Vericel Corporation | $38.22 | -1.97% | $1.96B | — |
| AUPH Aurinia Pharmaceuticals Inc. | $16.11 | -0.86% | $2.07B | — |
| ETON Eton Pharmaceuticals, Inc. | $58.01 | -1.39% | $1.59B | — |
| ADMA ADMA Biologics, Inc. | $9.42 | -0.31% | $2.18B | — |
| INVA Innoviva, Inc. | $20.74 | -1.85% | $1.53B | — |
| TRVI Trevi Therapeutics, Inc. | $15.91 | -4.39% | $2.26B | — |
| HRMY Harmony Biosciences Holdings, Inc. | $41.10 | -1.25% | $2.39B | — |
| SLS SELLAS Life Sciences Group, Inc. | $13.49 | -3.30% | $2.51B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for FUSN?
Negative return on equity (-49.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $16.4M recently.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 33 days old
- ● No filing on record
- ● No analyst coverage
Insider Activity
The most recent 12 insider filings for Fusion Pharmaceuticals Inc. break down as 12 sales and 0 purchases. On net that is roughly 2.3M shares disposed (about $16.4M), a signal worth weighing alongside the fundamentals.
Forward Outlook
Wall Street analysts project Fusion Pharmaceuticals Inc. revenue of about $11.1M for fiscal 2026, with EPS near $-1.59. The estimate reflects 4 contributing analysts.
Earnings Track Record
Fusion Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.5% below estimates on average.
Financial Health
Fusion Pharmaceuticals Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.47 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Fusion Pharmaceuticals Inc. stands at -49.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.7%, the inverse of the P/E and a quick read on earnings relative to price.
Fusion Pharmaceuticals Inc. (FUSN) Valuation Context
Valued at $1.83B, FUSN is classified as a small-cap stock.
Company Profile
Fusion Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hamilton, CA. The company is led by CEO John F. Valliant. FUSN has traded publicly since 2020.
FUSN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Mar 2024 | $0 | -$34M | -$0.40 |
Based on FMP financials and quantitative analysis
FUSN Latest News
-
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
benzinga · Mar 19, 2024
-
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
benzinga · Dec 27, 2023
-
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga · Dec 26, 2023
-
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga · Feb 14, 2023
Latest News
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Common Questions About FUSN
What happened to Fusion Pharmaceuticals Inc. (FUSN) stock?
Fusion Pharmaceuticals Inc. (FUSN) no longer trades on public markets. It was delisted in June 2024. The figures below are historical and are not a current quote.
Can I still buy FUSN shares?
No. FUSN stopped trading on public markets in June 2024, so the shares are not available through a broker. Anything you see quoted for FUSN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before FUSN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Fusion Pharmaceuticals Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.